Amisulpride - Dose, plasma concentration, occupancy and response: Implications for therapeutic drug monitoring

Acta Psychiatrica Scandinavica

Volumn 120, Issue 6, 2009, Pages 416-428

  Sparshatt, A ^a   Taylor, D ^a,b   Patel, M X ^b   Kapur, S ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amisulpride; Plasma concentration; Plasma level; Therapeutic drug monitoring

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PLACEBO; TRIMIPRAMINE;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; EMBASE; EXTRAPYRAMIDAL SYMPTOM; GROUPS BY AGE; HUMAN; INFORMATION RETRIEVAL; LOW DRUG DOSE; MEDLINE; MENTAL DISEASE; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 70449435368     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2009.01429.x     Document Type: Review

References (33)

1. Hiemke C. Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 2008 64 : 159 166.
2. Hiemke C, Dragicevic A, Grunder G et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004 26 : 156 160.
3. Mauri MC, Volonteri LS, Colasanti A et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007 46 : 359 388.
4. Coukell AJ, Spencer CM, Benfield P. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996 6 : 237 256. (Pubitemid 26306854)
5. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962 10 : 812.
6. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987 13 : 261 276.
7. Guy W. The Clinical Global Impressions Scale. In : Guy W, ed. ECDEU assessment manual for psychopharmacology Rev Ed. Rockville, MD : National Institute of Mental Health, 1976 : 157 169.
8. Puech A, Fleurot O, Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998 98 : 65 72.
9. Muller MJ, Eich FX, Regenbogen B, Sachse J, Hartter S, Hiemke C. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol 2008 23 : 278 286.
10. Muller MJ, Regenbogen B, Hartter S, Eich FX, Hiemke C. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 2007 41 : 673 679.
11. Muller MJ, Regenbogen B, Sachse J, Eich FX, Hartter S, Hiemke C. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry 2006 39 : 41 46.
12. Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2004 14 : 245 250.
13. Bressan RA, Erlandsson K, Jones HM et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003 160 : 1413 1420.
14. La FC, Meisenzahl E, Schmitt G et al. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. J Nucl Med 2005 46 : 1028 1033.
15. Meisenzahl EM, Schmitt G, Grunder G et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 2008 41 : 169 175.
16. Xiberas X, Martinot JL, Mallet L et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001 21 : 207 214.
17. Vernaleken I, Siessmeier T, Buchholz HG et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004 7 : 421 430.
18. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987 334 : 1 100.
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970 212 : 11 19.
20. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989 154 : 672 676.
21. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). 1974 U.S. Public Health Service Publication No. MH-9-17 Washington, DC : US Government Printing Office, 1974.
22. Chouinard G, Ross-Chouinard A, Jones BD. Extrapyramidal Symptom Rating Scale (ESRS). Can J Neurol Sci 1980 7 : 233.
23. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988 45 : 71 76.
24. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000 157 : 514 520.
25. Xiberas X, Martinot JL, Mallet L et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001 179 : 503 508. (Pubitemid 34031674)
26. Agid O, Mamo D, Ginovart N et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response. A double-blind PET study in schizophrenia. Neuropsychopharmacology 2006 32 : 1209 1215.
27. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997 170 : 18 22.
28. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999 156 : 610 616.
29. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992 49 : 538 544.
30. Nordstrom AL, Farde L, Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993 33 : 227 235.
31. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003 42 : 107 121.
32. BMJ Group and RPS Publishing. British National Formulary, 55th edn. London : BMJ Group and RPS Publishing, 2008.
33. Sanofi-Aventis. Summary of product characteristics. Solian. Available at: http://emc.medicines.org.uk/2008 (accessed on 17 March 2009).